Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Original Makers Suspected of Obstructing Generic Houses' Business: JFTC
July 3, 2006
- SURVEY 3 articles
July 3, 2006
- Generic Makers Concerned about Extension of Data Protection Period: IGPA Conference
July 3, 2006
- Epadel, Atelec Continue to Drive Mochida's Business
July 3, 2006
- 66th Annual Scientific Sessions of the American Diabetes Association
July 3, 2006
- Blopress Retained Rank as Top-selling Drug in FY2005
July 3, 2006
- Pediatric Clinical Trial of Ketek Temporarily Discontinued in US: sanofi-aventis
July 3, 2006
- COMMENTARY 3 atricles
July 3, 2006
- Toyama Chemical Initiates PI Trial of Anti-RA Drug T-5224
July 3, 2006
- Average Wage Hike in Pharma Industry Higher Than All-Industry Average: Survey
July 3, 2006
- Bayer Initiates PIII for Antithrombosis Drug Rivaroxaban
July 3, 2006
- Bayer Succeeds in Taking Over Schering AG
July 3, 2006
- SEMINAR
July 3, 2006
- BUSINESS NEWS IN BRIEF
July 3, 2006
- R&D NEWS IN BRIEF
July 3, 2006
- SEMIANR
July 3, 2006
- Wyeth Celebrates 100 Years of Vaccine Leadership
July 3, 2006
- Combined Income-Outlay Reform Proposal Calls for Review of Range of Health Insurance Benefits
July 3, 2006
- MEDICAL DEVICE NEWS IN BRIEF
July 3, 2006
- Industry Prepared to Pay More Feesto Increase Number of Reviewers: Dr Aoki
July 3, 2006
ページ
Japan will overhaul its R&D tax credit regime in its FY2026 reform, introducing a new strategic category alongside existing frameworks.…
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…